FLORONE E
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLORONE E (FLORONE E).
FLORONE E contains diflorasone diacetate, a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and reducing prostaglandin and leukotriene synthesis, resulting in anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Metabolized primarily in the liver via reduction, oxidation, and conjugation; hepatic enzyme pathways are involved but specific CYP isoenzymes are not well-defined. |
| Excretion | Primarily renal (<1% unchanged as metabolite) and biliary, with <1% excreted unchanged in urine. The remainder is metabolized and excreted in feces via bile. |
| Half-life | Approximately 2-4 hours (terminal) for the active moiety diflorasone; clinically, this supports twice-daily dosing for chronic skin conditions. |
| Protein binding | Extensive binding to plasma proteins, primarily albumin, with >90% bound. |
| Volume of Distribution | Not well characterized in humans; estimated to be 0.5-1.0 L/kg, suggesting distribution into total body water. |
| Bioavailability | Topical: variable, approximately 1-5% systemically absorbed through intact skin; increased 10-100% with occlusion, inflammation, or damaged skin. |
| Onset of Action | Topical application: noticeable improvement within 1-2 weeks; occlusive dressing may hasten onset to days. |
| Duration of Action | Clinical effect lasts 12-24 hours after topical application, with twice-daily dosing required; prolonged use may lead to tachyphylaxis. |
| Molecular Weight | 488.48 |
Apply a thin film to affected skin area twice daily. Not for ophthalmic, oral, or intravaginal use.
| Dosage form | CREAM |
| Renal impairment | No specific renal adjustment required; systemic absorption minimal with topical use. |
| Liver impairment | No specific hepatic adjustment required; systemic absorption minimal with topical use. |
| Pediatric use | Apply a thin film to affected area twice daily; limit treatment duration and avoid occlusive dressings due to increased systemic absorption. Safety not established in children <2 years. |
| Geriatric use | Apply a thin film to affected area twice daily; use caution due to thinner skin and increased potential for systemic absorption. Limit potency and duration of therapy. |
| 1st trimester | Topical corticosteroids of high potency like diflorasone diacetate have been associated with an increased risk of orofacial clefts in some observational studies, though data are limited. Use only if potential benefit justifies risk. |
| 2nd trimester | Topical corticosteroids are generally considered safer in the second trimester, but prolonged use or application to large areas should be avoided. Consider lower-potency alternatives. |
| 3rd trimester | High-potency corticosteroids may cause fetal growth restriction and adrenal suppression if used extensively. Avoid prolonged use. |
Clinical note
Comprehensive clinical and safety monograph for FLORONE E (FLORONE E).
| Placental transfer | Topical corticosteroids cross the placenta, but the extent varies with potency, formulation, and application area. High-potency agents have greater potential for transfer. |
| Breastfeeding | Systemic absorption from topical application is minimal, but caution is advised when applied to large areas, broken skin, or under occlusion. Use with caution and apply the smallest effective dose for the shortest duration. |
■ FDA Black Box Warning
Topical corticosteroids may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria, especially with prolonged use, large surface areas, occlusion, or pediatric use.
| Serious Effects |
Hypersensitivity to diflorasone diacetate or any component of the formulationUntreated bacterial, fungal, or viral skin infectionsRosaceaPerioral dermatitis
| Precautions | Systemic absorption may produce reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria. Use with caution in pediatric patients due to higher skin surface-to-body-weight ratio. Avoid prolonged use, occlusive dressings, and application to large areas. Monitor for local adverse reactions including atrophy, striae, and secondary infection. Not for ophthalmic use. |
| Food/Dietary | No known food interactions with topical diflorasone diacetate. Avoid excessive alcohol consumption if adrenal suppression is a concern, as alcohol may exacerbate corticosteroid-related side effects. |
Loading safety data…
| Lactation Rating | L2 (Safer if limited use) |
| Teratogenic Risk | Florone E (diflorasone diacetate) is a corticosteroid. Topical administration results in minimal systemic absorption. Animal studies have shown corticosteroids to be teratogenic (cleft palate) after systemic exposure. No adequate human studies. Risk cannot be excluded. Use only if potential benefit justifies risk. Fetal risk cannot be ruled out (Category C). First trimester: theoretical risk, avoid large areas or occlusive dressings. Second/third trimester: use lowest effective dose, shortest duration. |
| Fetal Monitoring | Monitor for signs of adrenal suppression in mother and neonate if prolonged or extensive use. Monitor fetal growth by ultrasound if chronic high-dose use. Monitor maternal blood pressure and glucose due to potential systemic effects. |
| Fertility Effects | No specific human data on fertility effects. Animal studies with corticosteroids have shown impaired fertility at high systemic doses. Topical use is unlikely to impact fertility due to low systemic absorption. |
| Clinical Pearls | FLORONE E (diflorasone diacetate) is a high-potency topical corticosteroid. It should be applied sparingly to affected areas only; avoid prolonged use, especially on the face, intertriginous areas, or under occlusive dressings, to reduce systemic absorption and local side effects like atrophy. Use for no longer than 2 weeks continuously unless directed otherwise. Monitor for HPA axis suppression with large doses or extended use. |
| Patient Advice | Apply a thin layer to the affected skin area only, not to healthy skin. · Do not cover the treated area with bandages or wraps unless instructed by your doctor. · Wash hands after applying, unless treating hands. · Use only as long as prescribed; do not use for more than 2 weeks without re-evaluation. · Avoid contact with eyes, mouth, or broken skin. · Report any signs of skin thinning, stretch marks, or infection. · Do not use for other skin conditions without medical advice. |